Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy
International Immunopharmacology · 2023-03 · 116 · 109569
DOI: 10.1016/j.intimp.2022.109569 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023-03. Verfasst von SriPragnya Cheruku und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal- 576104, Karnataka, India. Hauptthemen laut MEDLINE: Tumor-Associated Macrophages, Colorectal Neoplasms. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 192 Literaturangaben. Gefördert von: Indian Council of Medical Research, Manipal Academy of Higher Education.
Abstract (Originalsprache)
Tumor-associated macrophages (TAMs) constitute the most prolific resident of the tumor microenvironment (TME) that regulate its TME into tumor suppressive or progressive milieu by utilizing immunoediting machinery. Here, the tumor cells construct an immunosuppressive microenvironment that educates TAMs to polarize from anti-tumor TAM-M1 to pro-tumor TAM-M2 phenotype consequently contributing to tumor progression. In colorectal cancer (CRC), the TME displays a prominent pro-tumorigenic immune profile with elevated expression of immune-checkpoint molecules notably PD-1, CTLA4, etc., in both MSI and ultra-mutated MSS tumors. This authenticated immune-checkpoint inhibition (ICI) immunotherapy as a pre-requisite for clinical benefit in CRC. However, in response to ICI, specifically, the MSIhi tumors evolved to produce novel immune escape variants thus undermining ICI. Lately, TAM-directed therapies extending from macrophage depletion to repolarization have enabled TME alteration. While TAM accrual implicates clinical benefit in CRC, sustained inflammatory insult may program TAMs to shift from M1 to M2 phenotype. Their ability to oscillate on both facets of the spectrum represents macrophage repolarization immunotherapy as an effective approach to treating CRC. In this review, we briefly discuss the differentiation heterogeneity of colonic macrophages that partake in macrophage-directed immunoediting mechanisms in CRC progression and its employment in macrophage re-polarization immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal- 576104, Karnataka, India.
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education, and Research, Hajipur, Export Promotions Industrial Park (EPIP), Industrial area, Hajipur, Vaishali, 844102, Bihar, India.
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education, and Research, Hajipur, Export Promotions Industrial Park (EPIP), Industrial area, Hajipur, Vaishali, 844102, Bihar, India. Elect…
Förderung
- Indian Council of Medical Research
- Manipal Academy of Higher Education
Zitieren
APA
Cheruku, S., Rao, V., Pandey, R., Rao Chamallamudi, M., Velayutham, R., & Kumar, N. (2023). Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy. International Immunopharmacology, 116, 109569. https://doi.org/10.1016/j.intimp.2022.109569
Vancouver
Cheruku S, Rao V, Pandey R, Rao Chamallamudi M, Velayutham R, Kumar N. Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy. International Immunopharmacology. 2023;116:109569. doi:10.1016/j.intimp.2022.109569
BibTeX
@article{Cheruku2023,
author = {Cheruku, SriPragnya and Rao, Vanishree and Pandey, Ruchi and Rao Chamallamudi, Mallikarjuna and Velayutham, Ravichandiran and Kumar, Nitesh},
title = {Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy},
journal = {International Immunopharmacology},
year = {2023},
volume = {116},
pages = {109569},
doi = {10.1016/j.intimp.2022.109569}
}
EUVIMED